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Abstract Twenty-three adolescents with psychotic disorders, aged from 13 to 18 years,
participated in a 12-week open label trial (17 adolescents completed the study) in order to
examine the impact of quetiapine on clinical status and cognitive functions (encompassing
processing speed, attention, short-term memory, long-term memory and executive func-
tion). An improvement in Clinical Global Impression and Positive and Negative Symptom
Scale (P’s B 0.001) was observed. In addition, after controlling for amelioration of
symptoms, a significant improvement was observed on one executive function (P = 0.044;
Trail Making Part B). The remaining cognitive abilities showed stability. In addition, we
observed an interaction between quetiapine doses ([300 mg/day or \300 mg/day) and
time, where lower doses showed more improvement in verbal short-term memory
(P = 0.048), inhibition abilities (P = 0.038) and positive symptoms (P = 0.020). The
neuropsychological functioning of adolescents with psychotic disorders remained mainly
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stable after 12 weeks of treatment with quetiapine. However, lower doses seemed to have a
better impact on two components of cognition (inhibition abilities and verbal short-term
memory) and on positive symptoms.
Keywords Schizophrenia  Psychosis  Adolescence  Cognition  Neuropsychology 
Quetiapine  Antipsychotic treatment  Cognitive enhancer
Introduction
Psychotic disorders comprise a wide spectrum of disabilities ranging from positive
(hallucinations, delusions) and negative (alogia, anhedonia, avolition, flat affect) symptoms
[1] to cognitive impairments in attention, processing speed, working memory, long-term
verbal memory and executive functions [2–6]. These cognitive deficits are related to poorer
functional outcome [7, 8]. More specifically in adolescents with psychotic disorders, these
cognitive disabilities interfered with a period of important educational, social and emo-
tional development [9]. Therefore adolescents suffering from psychotic disorders are a
major concern for clinicians or mental health institutions having to find the most optimal
treatments alleviating symptoms as well as being well adapted and self satisfactory for this
age group.
Atypical antipsychotics (e.g. olanzapine, risperidone, quetiapine) have shown good
tolerability and proven to be effective in treating negative and positive symptoms as well
as promising improvement on cognitive impairment in adults with schizophrenia [10–14].
In adolescents with psychotic disorders, the efficacy of atypical antipsychotics on positive
and negative symptoms has also been proven in different studies [15–19]. More specifi-
cally, in this population, quetiapine has been shown to reduce symptoms, to be well
tolerated and to be associated with low weight gain and low extra-pyramidal symptoms
occurrence [17, 20–22]. Atypical antipsychotics share some pharmacological properties in
that almost all of them are antagonists at dopaminergic D2- and serotonergic 5-HT2a
receptors, in relationship with their effects on positive symptoms and negative symptoms,
respectively [23]. Quetiapine shares structurally some common properties with the anti-
psychotic drug loxapine, which is metabolized by N-demethylation to the antidepressant
drug amoxapine [24]. Quetiapine is one of the atypical antipsychotic drugs also introduced
for the treatment of bipolar depression and as that, it is considered to be a first line option in
international guidelines [25]. Interestingly, quetiapine similarly to loxapine is also
demethylated: its metabolite norquetiapine [24] is a potent norepinephrine reuptake
inhibitor and a partial 5-HT1a agonist. Serotonin and noradrenaline are implicated in
cognitive mechanisms [26, 27]. To the best of our knowledge, only one comparative,
randomized, single-blind, 6-month study explored cognitive improvement related to
treatment by quetiapine compared to olanzapine in an adolescent population [9]. Results
revealed no amelioration in attention, working memory, learning and memory or executive
functions. Therefore, further clinical trials are needed in order to replicate and confirm
these results.
Thus, the present clinical study aimed at measuring the impact of quetiapine on cog-
nitive functions and clinical status in adolescents with psychotic disorders. The impact of
quetiapine on cognitive functions was assessed by neuropsychological tests before and
after 12 weeks of quetiapine treatment. This investigation is part of a study on the clinical
effectiveness and tolerability of quetiapine in adolescents with non-affective psychotic
disorders [28].
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Methods
Study Design
The comprehensive design of this study as it was presented in details elsewhere [28] is
summarized as follows: this was a two-site (Lausanne and Bern university hospitals) open-
label trial in adolescents with psychotic disorders, in which assessments of cognitive
impact and clinical efficacy of quetiapine were performed over 12 weeks. The study was
approved by the Ethical Committee of the Lausanne University Hospital. Written informed
consent was obtained prior to any study procedures by all patients and parents or legal
representatives as required. Treatment discontinuation and study withdrawal could be
motivated at any time by the subjects or the investigators.
Inclusion Criteria
Adolescents (13–18 years old) who fulfilled the DSM IV criteria for schizophrenia
(295.10, 295.20, 295.30, 295.60, 295.90), schizophreniform disorder (295.40), schizo-
affective disorder (295.70), delusional disorder (297.1), brief psychotic disorder (298.8),
substance-induced psychotic disorder (293.xx), psychotic disorder NOS (298.8), mood
disorders with psychotic features (296.x4) and who had no current medication or for whom
initial antipsychotic treatment showed lack of efficacy or poor tolerance were targeted.
Exclusion Criteria
Subjects were excluded from the study if they showed (1) evidence of substance abuse
(positive urine screening to opiates or ecstasy). Some cannabis consumption was not
considered as exclusion criteria as this behavior is frequent in this population, for which
effective treatments are needed; (2) a history or present condition of organic mental
disorders, (3) mental retardation (IQ \ 70, defined as need for special education, assessed
through a screening of the medical records about the activities before the first psychotic
episode), (4) clinically meaningful non stable cardiovascular, (5) hepatic or renal diseases,
(6) leucopenia (WBC \ 4,000/mm3) or (7) pregnancy, or if they were currently enrolled in
another medical trial.
Patients
A total of 23 participants were screened and selected in the study, 17 from center one
(Lausanne) and 6 from center two (Berne). The adolescents were aged between 13 and
18 years (Mean ± SD: 15.8 ± 1.38 years), 17 of them were male (6 females) and 20 were
Caucasian. DSM-IV diagnoses included schizophrenia (7), schizophreniform disorder (6),
schizoaffective disorder (1), psychotic disorder not otherwise specified (6), delusional
disorder (2) and brief psychotic disorder (1). All 23 subjects received quetiapine, 17
completed the treatment (Completer) and 6 discontinued early (Non-completer) due to
consent withdrawal (3), lack of compliance (1), lack of efficacy (1) and the occurrence of a
serious adverse event (1).
Psychiatric comorbidities were present in the medical history of 11 patients: Eating
disorder (1 patient), obsessive compulsive disorder (1), sexual abuse by an adult (1), sub-
stance abuse (1), suicide attempts (1), conduct disorder (2), depression and self-injuries (1),
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depression (1), onset psychosis as a child (1), social anxiety (1). 14 patients presented other
than psychiatric problems in their medical history: Dermatological pathologies (5), mus-
culoskeletal system (4), endocrinological system (3) (including 2 patients with hyperpro-
lactinemia), peripheral nervous system (2), respiratory system (2), gastro-intestinal tract (1),
cardiovascular system (1), blood (1) and allergy (1).
Premedications and Concomitant Medications
Concomitant medications were given only if considered necessary for the participants’
safety or well-being. A failure of previous ongoing antipsychotic treatments lead to
enrolment in the present study and so was discontinued. Eight participants received anti-
psychotic medication before the start of the quetiapine treatment: only olanzapine (3); only
risperidone (3); olanzapine and risperidone (1); olanzapine, levomepromazine and zuc-
lopenthixol (1). A wash-out period of at least 24 h was observed for any participant
receiving prior antipsychotic treatments. In addition, for drug-naı¨ve patients, a short period
of treatment with the benzodiazepines clorazepate, alprazolam or diazepam could be
conducted if needed.
Hepatic enzyme-inducing agents (e.g. carbamazepine, barbiturates, glucocorticoids) had
to be avoided as concomitant medication. No other psychotropic medication was allowed
except alprazolam, diazepam, clorazepate in case of severe agitation, chloral hydrate in
case of invalidant insomnia, biperidene when appropriate.
Medication Dosing
Doses were adjusted by senior psychiatrists of both sites (L.H. and U.P.) in function of
efficacy and tolerability in order to improve the compliance and to limit side effects (as
sedation, for example). Quetiapine doses (computed by summing the total amount of
administered doses divided by the number of days of exposure) ranged between 42 and
858 mg, the mean daily dose was 350 ± 213 mg/days. Mean exposure time to quetiapine
was 77 ± 28 days, with a minimum of 9 and a maximum of 106 days of exposure. Plasma
concentrations of quetiapine as assayed by a previously described method [28] were
213 ± 277 ng/ml at week 12 (n = 14). As about half of the patients received doses lower
than 300 mg/day, in the final part of the analyses the adolescents were split in function of
the received doses ([300 mg/day or \300 mg/day) in order to explore for possible dif-
ferences of the effect of quetiapine doses on cognition and clinical status. The mean doses
for the ‘‘low doses group’’ (n = 8) were 136 ± 82 mg/day (range 42–273 mg/day) and of
498 ± 130 mg/day (range 339–858 mg/day) for the ‘‘high doses group’’ (n = 9). Plasma
levels of quetiapine confirmed the repartition of the adolescents (at week 12 it was of
14 ± 9 ng/ml and of 363 ± 287 ng/ml for the lower and higher doses group, respectively)
in that, as expected, plasma levels of quetiapine were lower in the low dose than in the high
dose group.
Assessments
Clinical Status
Participants were assessed with the Positive and Negative Symptom Scale (PANSS),
assessing positive and negative symptoms as well as general psychopathology in subjects
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with schizophrenia and related disorders [29]. Clinical efficacy was evaluated with the
Clinical Global Impression-Severity of illness scale (CGI) [30]. Evaluations were con-
ducted both at baseline and at study week 12.
Neurocognitive Test Battery
A comprehensive test battery was administered by a trained neuropsychologist at baseline
and after 12 weeks of treatment. The psychometric tests were chosen because they rep-
resent main functions which can be altered in psychotic disorder, i.e. processing speed,
attentional abilities, memory abilities and executive function [2, 5, 6].
Processing speed ability was assessed with the Trail Making Test—Part A [31] where
digits ranging from 1 to 25 had to be connected with a continuous line. In addition, the part
of the Stroop task, where images were to be named, was also used to assess processing
speed abilities. The time to realize the tests were recorded.
Selective and Sustained Attention were assessed with the Continuous Performance Test
(CPT) degraded version [32, 33]. In this test, stimuli were presented to the participant who
had to detect (by pressing on a key response) the occurrence of a target stimulus during an
8-min period. The scores were the hit rate (mean success rate), the false alarm rate
(responding to interfering stimuli), d0 (computed from the proportion of hits and false
alarms) representing a measure of signal/noise discrimination (i.e. the ability to discrim-
inate between target and non-target).
Short term memory ability was assessed with two tests. Firstly, the Audio Span Test
[34] was administered. In this task, clusters of numbers were read by the examiner and had
to be repeated by the participant. Secondly, in the Visuo-spatial Span Test [35] visuo-
spatial sequences were performed by the examiner and repeated by the subject in the same
order. The scores were made of the maximal cluster of numbers or the maximal visuo-
spatial sequence correctly repeated.
Long term memory ability was assessed with two tests. Firstly, the Rey Auditory Verbal
Learning Test [36] which consisted in a list of 15 words that the participant had to learn
through 5 immediate recall. Then, a delayed recall was required. The score used for this
task was the number of words correctly recalled in the delay recall. Secondly, the complex
figure of Rey [37] was used. This task consisted in copying and recalling a complex
geometrical figure. The score was made out of the correct recall of the elements of the
geometrical figure.
Executive functions were assessed with three tests. First, in the Verbal Fluency Task
[38] as many words as possible of one category (letter M or animal) had to be generated in
a limited time (60 s). The score was made of the total number of correct words expressed
in both part (with the letter M and animal). Secondly, the Trail Making Test—Part B [31]
was administered. In this task, participants had to connect digits and numbers alternatively.
The time to realize this task and errors were recorded. The interference condition of the
Stroop task requires suppressing the automatic response of word learning in favor of the
less automatic process of object naming. Speed of naming (time score) and the number of
interference errors were recorded.
Additional Measures
Urine sample was asked for illicit drug detection at week 0. Semi-quantitative urine
analyses included the following substances: cannabis, benzodiazepines, opiates, cocaine,
methadone and amphetamines. In addition, the substance use and frequency before and
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during the study were assessed by the substance use questionnaire derived from the
Adolescent Drug Abuse Diagnosis [39]. Thus, at baseline, one participant injected heroin,
and eight patients drunk alcohol 1–5 times during the past month (usually 1–6 drinks per
day). Eleven participants smoked every day tobacco during the past 6–48 months. In
addition, 10 participants smoked regularly [several times per week (n = 5) or per day
(n = 5)] cannabis during the past 12–48 months. Two participants had to be considered as
polydrug users, as they reported to drink alcohol and smoke cannabis and tobacco, as well
as to intake amphetamines, tranquilizers, cocaine, hallucinogens and phencyclidine.
Statistical Analysis
Descriptive statistics were provided for dependant variables. Everywhere, if not otherwise
mentioned, data were presented as means ± SD. As the data suit a Gaussian distribution,
parametric tests were used. First, we tested the effect of antipsychotic pre-medication using
independent tests of Student on the evaluation at baseline and at the end of the study. Then
dependent sample tests of Student assessed the changes in performance on neuropsycho-
logical tests. After testing for main effect of quetiapine on cognition, analyses of covari-
ance (with the amelioration of the symptoms as covariate) were computed [40]. Then,
correlation analyses were conducted between changes in clinical status and changes in
cognitive abilities. After that, 2 (quetiapine doses: higher or lower than 300 mg/day) 9 2
(time: Baseline vs. at week 12) analyses of variance (ANOVA) were conducted in order to
observe possible interaction effects between time and quetiapine doses. Finally, differences
between patients who did (completer) and did not complete (non-completer) the study were
assessed with independent sample tests of Student at baseline.
Results
Pre-Medication Effect
The effect of previous antipsychotic medication was tested at baseline and at the end of the
study. Results revealed no significant differences on clinical status, cognitive abilities or
rate of non completers between the participants who take antipsychotic medication prior to
the study versus the participants who did not receive any antipsychotic before the study.
Impact of Quetiapine on the Clinical Status
At the end of the study, significant reduction was observed on the three subscales of the
PANSS (positive, P \ 0.001; negative, P = 0.004; general psychopathology subscales,
P \ 0.001). In addition, the severity of the symptoms decreased during the 12 weeks
treatment (P \ 0.001), (Table 1).
Impact of Quetiapine on Cognition
Changes on neuropsychological testing are displayed in Table 2. A statistically significant
improvement in processing speed was found regarding the denomination part (picture
naming) of the Stroop task (P = 0.002) and the Part A of the Trail Making Test task
showed marginal differences (P = 0.065). However, after controlling for the amelioration
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of the symptoms (changes in CGI entered as covariate), this effect was only a trend
regarding the denomination part of the Stroop task, F(1, 16) = 3.54; P = 0.078;
gp
2 = 0.18, and disappeared in the Part A of the Trail Making Test F(1, 15) = 0.781;
P = 0.391; gp
2 = 0.00. The Part B of the Trail Making Test showed significant differences
between both administration (P = 0.016). This differences remained significant even after
controlling for the amelioration of the severity of the symptoms (changes in CGI entered as
covariate), F(1, 15) = 4.82; P = 0.044; gp
2 = 0.24. Small changes that did not reach
significance were found for the remaining tests. These differences were not influenced by
substance abuse as well as by comedication as there were no significant differences in
function of these variables, both at baseline and after 12 weeks.
Table 1 Descriptive scores for the symptomatology
Scale N Baseline At week 12 Changes from baseline to week 12
Mean (SD) Mean (SD) Mean (SD) t P
CGI Severity 20 4.90 (0.64) 3.35 (0.99) 1.55 (1.00) 6.94 \0.001
PANSS Positive 20 22.60 (5.74) 16.85 (6.85) 5.75 (5.25) 4.90 \0.001
PANSS Negative 20 26.20 (5.99) 21.25 (5.43) 4.95 (5.72) 3.87 0.001
PANSS Global 20 48.30 (7.98) 37.55 (9.23) 10.75 (10.23) 4.70 \0.001
Mean scores on Clinical Global Impression-Severity of illness scale (CGI Severity) and on the general
psychopathology (PANSS Global), negative symptoms (PANSS Negative) and positive symptoms (PANSS
Positive) subscales of the PANSS: at baseline, at week 12 and changes
Table 2 Mean raw scores on neuropsychological testing: baseline, at week 12 and changes
Cognitive
domain
Test N Baseline At week 12 Change from baseline to week 12
Mean (SD) Mean (SD) Mean (SD) t P
Processing
speed
TMT A 17 51.35 (15.31) 46.35 (13.89) -5.00 (10.41) 1.98 0.065
Stroop image 18 40.28 (8.87) 37.28 (7.63) -3.00 (3.58) 3.55 0.002**
Attention Hit rate 14 67.32 (22.20) 67.80 (19.46) 0.47 (15.41) -0.12 0.910
FA 14 12.24 (13.02) 11.43 (12.96) -0.81 (2.78) 1.10 0.293
d0 14 1.95 (1.21) 1.99 (1.13) 0.04 (0.59) -0.24 0.813
Short term
memory
Auditory
span
17 5.88 (0.92) 5.88 (0.1.16) 0.00 (1.00) 0.00 1.000
Visuo-spatial
span
17 5.41 (1.12) 5.59 (1.22) 0.18 (1.42) -0.51 0.616
Long term
memory
15 Words 17 11.24 (3.01) 10.35 (3.79) -0.88 (3.46) 1.05 0.273
Rey figure 17 19.88 (7.93) 22.06 (6.37) 2.18 (7.91) -1.13 0.301
Executive
functions
Fluency 17 32.53 (5.62) 33.12 (8.78) 0.59 (7.55) -0.32 0.752
Stroop
inhibition
18 59.17 (22.81) 51.94 (10.07) -7.22 (19.18) 1.60 0.129
TMT B 17 81.41 (27.53) 68.35 (26.86) -13.06 (20.06) 2.68 0.016*
TMT Part A, Trail Making Test Part A, time in seconds; Stroop image, Stroop task, denomination of image
part, time in seconds; Hit rate, CPT, mean success rate, percentage; FA, CPT, false alarm rate, percentage;
d’, CPT, sensitivity; auditory span, number of recalled numbers; visuospatial span, number of sequences
correctly recalled; 15 words, Rey Auditory Verbal Test, number of words correctly recalled; Rey figure,
complex figure of Rey, points; fluency; number of words expressed; Stroop inhibition, Stroop task, inter-
ference part, time in seconds; TMT B, Trail Making Test Part B, time in seconds. * P \ 0.05; ** P \ 0.01
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Relation Between Cognition and Clinical Status
Then, we conducted correlation analyses with Pearson’s correlation in order to observe if
the improvement in clinical status were related to improvement in the cognitive abilities.
The analyses revealed no significant correlations between the improvement in symptom-
atology and cognition.
Impact of the Doses on the Changes in Cognition and Clinical Status
The quetiapine doses’ groups did not differ in their number of male/female (v(1)
2 = 0.2,
P = 0.658), substance abuse (v(1)
2 = 1.7, P = 0.193) or concomitant medication (v(1)
2 =
2.2, P = 0.138). Thus, 2 (doses: higher or lower than 300 mg/day) 9 2 (time: baseline vs.
after 12 weeks) ANOVAs tested the effects of doses on the improvement of cognition and
clinical status. The interaction effect was of particular interest in order to observe different
influence of quetiapine doses on cognition and clinical status. The results revealed a
significant interaction effect on the number of words recalled on the audio span task,
F(1, 15) = 4.64; P = 0.048, gp
2 = 0.24; on the time to realize the interference part of the
Stroop task, F(1, 16) = 5.14; P = 0.038, gp
2 = 0.24; and on the positive scale of the
PANSS, F(1, 17) = 6.53; P = 0.020; gp
2 = 0.28. Figure 1 illustrated these interactions.
One could observe that lower doses showed more efficient improvement on verbal
memory, inhibition and positive symptoms. However, t-test comparing the groups at
baseline or after 12 weeks did not reveal significant differences.
Completers Versus Noncompleters
At baseline, no significant difference between the patients who did and did not complete
the study was found regarding the PANSS and CGI. Regarding the cognitive measure, the
completers differed from the non-completers in their performances in the fluency task
(P = 0.005), non-completers giving less responses than completers.
Discussion
In this study, the clinical impact of quetiapine on positive and negative symptoms, as well
as on general psychopathology (Table 1) confirms previous findings about positive effects
of atypical antipsychotic medication [18, 19, 41] and of quetiapine both in adults [14, 20–
22] and in adolescents [9, 17]. With regard to the effects of quetiapine on cognition, after
12 weeks of treatment, a significant improvement was observed in the executive function,
more specifically in shifting abilities (Table 2), which remained significant after control-
ling for symptoms amelioration. This ability to shift between two or more tasks, operations
or mental sets, refers to executive functions. Executive functions are important processes
when using routines is not possible and to serve goal-directed behavior [42]. Thus,
improvement in such abilities allows for better planning and problem-solving, for example.
In contrast, processing speed seemed to improve, but this improvement was more related to
the amelioration of the symptoms as the effect disappeared after controlling for this
amelioration. Short-term memory, long-term memory and attention remained stable. These
results were similar to those found in adults with psychosis, for whom significant executive
functions improvements related to quetiapine’s treatment have been found in shifting
[14, 43] and inhibition abilities [44]. However, the present results contrast with those
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obtained by Robles et al. [9] comparing the effect of quetiapine and olanzapine on cog-
nitive abilities of adolescents over 6 months who reported no amelioration of these
abilities.
Treatment doses used in this study (350 ± 213 mg/day quetiapine) were inferior to
those usually administered in the adult population. However, a high variability in the
administered quetiapine doses was also reported in previous trials with adolescent patients:
532.8 ± 459.6 mg/day (reported in [9, 17]). Regarding the treatment’s doses, inconsistent
results were found in adult populations. Thus, Arvanitis and Miller [45] demonstrated that
doses from 150 mg/day were efficient in adult populations to reduce positive symptoms but
that doses of 300 mg/day at least are required to decrease negative symptoms. In contrast,
Small et al. [46] demonstrated in adult populations that lower doses than 250 mg/day might
not be less efficient in order to improve positive symptoms. In adolescent populations the
effective doses in order to improve clinical status seemed to vary between studies. Shaw
et al. [21] administered 467 mg/day (ranging from 300 to 800 mg) and Swadi et al. [22]
reported a mean administered dose of 607 mg/day and reported that 4 participants out of 11
had to receive higher doses than 1,000 mg to be effective. However, in the present study,
although the whole group showed improvement in clinical status, the adolescents who
Fig. 1 Quetiapine doses by time interactions. Note Interaction effect between quetiapine doses and time for
the auditory span (a), for the interference part of the Stroop task (b), and for the positive symptoms scale of
the PANSS (c)
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tolerated only lower doses seemed to show more improvement in positive symptoms than
the patients receiving higher doses.
With regard to the cognitive abilities, the same interaction was found (Fig. 1) in inhi-
bition and verbal short-term memory. Thus, participants receiving lower doses of quetia-
pine demonstrated more improvement in verbal short-term memory and inhibition of
automatic response compared to adolescents with higher doses of quetiapine. Both cog-
nitive abilities are important in everyday life. Thus, short-term retention of information
helped to restrain information in many situations of life and resisting to automatic behavior
in favor of a non dominant one allowed adopting more appropriate behavior. Contrast-
ing results were found in adults with schizophrenia. Velligan et al. [11] suggested that
600 mg/day doses of quetiapine allow a higher improvement in executive function and
verbal memory than lower doses (300 mg/day). Nevertheless, to our knowledge, no study
explored the efficiency of different doses in adolescent populations. Thus, quetiapine could
have different impact according to the chronicity of the illness and the age of the patient.
Indeed, some studies demonstrated that compared to those with chronic illness, treatment,
even with lower doses (often 50% lower than doses for chronic patients), of individuals
in first-phases of psychosis tended to be more efficient in terms of symptoms reduction
[47–49]. These effects could be explained by the changed sensitivity of D2 receptors due to
long-term treatment [50]. Considering all above studies, further trials are warranted to
determine the more effective doses of quetiapine in order to treat psychotic symptoms and
improve cognitive abilities in adolescent populations.
The action of quetiapine in the brain could help us to understand this result. Quetiapine
is associated with the occupancy of D2 (dopamine) and 5HT2a (serotonin) receptors which
mediates antipsychotic effect (for a recent review see [51]). In adult populations, data
suggested that lower doses than 450 mg/day did not allow an adequate occupancy of the
D2 receptor [46, 52–54] and so would not be effective. However, no study explored the
effect of quetiapine on brain of adolescents where the necessary occupancy of D2 and
5HT2a receptors could be sufficient at lower doses of quetiapine or that the effective
occupancy of receptor could be reached with lower doses. Further studies are needed to
determine the efficient doses of quetiapine to have a sufficient occupancy of D2 receptor.
These considerations, however, neglect the fact that, as presented in the Introduction,
quetiapine also exerts by its metabolism to norquetiapine, agonistic serotonergic (as a
partial 5-HT1a) and noradrenergic (as a noradrenaline reuptake inhibitor) effects [24, 51].
These neurotransmitters have an important impact on psychomotor and vigilance func-
tions, respectively [52]. Due to the non-availability of norquetiapine for analytical pur-
poses, it could not be analyzed in this study, but a previous investigation shows that in
schizophrenic patients treated with quetiapine, norquetiapine is present in measurable
concentrations both in plasma and CSF [55]. In addition, the treatment resulted in a 35 and
33% increase in CSF 5-HIAA and MHPG, metabolites of serotonin and noradrenaline,
respectively. Moreover, significant correlations were calculated between norquetiapine
concentrations in CSF and the changes of 5-HIAA (P \ 0.01) and MHPG (P \ 0.03) CSF
levels.
Limitations of the present study emanate from the study design. Despite the fact that the
study was planned and executed by independent practitioners and data analysis was ver-
ified by an independent statistician, this was an open-label study, with no control group.
There is no indication of spontaneous recovery. Moreover, associations between cognitive
and clinical improvements are likely to appear at a general level, but are not necessarily
found at the individual level [56]. In addition, as the group was divided a posteriori in
function of the effectiveness and side effect of quetiapine treatment, further studies are
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needed, in order to explore in more details the effect of low doses of quetiapine on
cognition and clinical status. Finally, practice effect may have interfered in the evaluation
of the cognitive improvement. However, a study conducted on schizophrenic outpatient
showed a very low rate of practice effect over 10 weeks on tests used in the present study
such the TMT, HVLT or the forward and backward digit recall [57]. Consistently, a
previous study reported a lack of test–retest effect in first-episode schizophrenic patients
[14]. A further limitation of the study is the prior treatment by other antipsychotics for
some patients (N = 8). However, those patients were enrolled because of a lack of efficacy
of the treatment and therefore during the study the patients were treated only with que-
tiapine. Furthermore, our analyses revealed no differences at baseline or at the end of the
study when we compared the patients who take previously an antipsychotic or those who
did not take previously an antipsychotic medication.
In conclusion, as cognitive functions play a major role in predicting psycho-social
functioning [7, 8] and as adolescence is a critical period of development in many aspects of
life, it is important to develop effective therapeutic programs which target cognitive
impairments. Given the greater cerebral plasticity in this age-group, approaches which
combine antipsychotic medication and cognitive remediation may enhance treatment
effects and may be worth investigating. However, further studies are needed to ensure that
the core feature, i.e. cognitive dysfunctions, in adolescence psychosis can be targeted by
medication and/or cognitive remediation, and that substantial improvement is followed by
better functional outcome. Finally, by its unique pharmacological profile, the effects of
quetiapine and especially of norquetiapine should be further examined, also in animal
models of cognitive functions.
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